Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.
about
Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysisLong term follow-up of drug resistant and drug susceptible tuberculosis contacts in a Low incidence setting.Adverse events in healthy individuals and MDR-TB contacts treated with anti-tuberculosis drugs potentially effective for preventing development of MDR-TB: a systematic review.Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA.Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.Current development and future prospects in chemotherapy of tuberculosisFirst report of multi-drug resistant tuberculosis in a systemic lupus erythematosus patient.Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.Multidrug-resistant tuberculosis in military recruits.The burden of adverse events during treatment of drug-resistant tuberculosis in NamibiaEarly bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.Consensus Statement on Research Definitions for Drug-Resistant Tuberculosis in Children.Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases.Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.Multidrug-resistant tuberculosis outbreak in an Italian prison: tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays.
P2860
Q28478920-C08A0AA6-26F1-4157-A3CE-B8659203E4C7Q34454109-B1354D8D-CDA0-4BEE-BDDD-C737F0EC9354Q34551560-BA978C6D-76BB-4FE6-AADD-06E815CAC916Q35130341-0720CC1B-7328-448C-806E-F4A652E10D76Q35527885-AFD33FEF-7D2C-4032-86CE-3993B758B082Q35705874-3E568069-4D38-4732-9B0C-6B9AA57F7F57Q35738246-93A2ABEB-3EF5-44DD-9D97-19472A75C00DQ35754209-1F4DA649-1865-4F0B-9C0D-847F3B13E784Q36029421-AE22DCBC-A59D-4A14-A612-B07A8E44967BQ36317060-B4A60A88-A317-4099-B2EB-2B81D2D04587Q36492180-19F3FC9C-95FA-408A-8873-6B6AE7B65092Q36880164-C52911BD-56EF-4F34-B30F-1B04771B54E1Q37074826-32898EAF-718A-46AB-9E2E-F9CABB63AF3AQ37278221-1930146E-72A6-43F2-9F20-596BD0F45857Q37613267-0E0FF734-BA90-4508-9359-0F9EC94F0ABFQ38886442-F6461E98-A612-4643-9FF0-4BA71A57CCDAQ40660539-B04AA460-5C98-466C-AB25-476175E74F34
P2860
Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Adverse events associated with ...... tidrug-resistant tuberculosis.
@ast
Adverse events associated with ...... tidrug-resistant tuberculosis.
@en
type
label
Adverse events associated with ...... tidrug-resistant tuberculosis.
@ast
Adverse events associated with ...... tidrug-resistant tuberculosis.
@en
prefLabel
Adverse events associated with ...... tidrug-resistant tuberculosis.
@ast
Adverse events associated with ...... tidrug-resistant tuberculosis.
@en
P2093
P2860
P1476
Adverse events associated with ...... tidrug-resistant tuberculosis.
@en
P2093
Anne Holbrook
Lisa R Dolovich
Lori Whitehead
Tina Papastavros
P2860
P304
P407
P577
2002-07-01T00:00:00Z